Developing novel anti-cancer agens by high throughput chemical screens for small molcules that modulate the pro-survival

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/305536

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer is the second commonest cause of deaths in our community. Unfortunately, treatment often fails or causes unwanted side effects. This proposal seeks to discover and develop a novel class of anti-cancer drugs that act by directly activating programmed cell death (apoptosis). The Bcl-2 proteins are key regulators of cell death and by exploiting knowledge about these prime targets for cancer therapy, we aim to discover drugs that are potentially of considerable medical and commercial value.

Funded Activity Details

Start Date: 01-01-2004

End Date: 01-01-2004

Funding Scheme: NHMRC Development Grants

Funding Amount: $125,000.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Cell Development, Proliferation and Death

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Bcl-2 | Cancer | Cell death/apoptosis | drug design | drug development

Related Links